Patents by Inventor Lars Mattsson
Lars Mattsson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230028051Abstract: The present invention relates to a liquid chromatography system configured to operate with at least one column and configured for purification of a sample comprising a target product using a predefined process. The liquid chromatography system comprises a controller configured to: control the operation of the chromatography system to run the predefined process; retrieve column data accessible from a data storage, the column data being specific to each column; and adapt at least one process parameter of the predefined process for each column based on column data. Whereby the predefined process is adapted to each column to obtain the target product and maintain the performance of the liquid chromatography system.Type: ApplicationFiled: October 6, 2022Publication date: January 26, 2023Inventors: Jens Widehammar, Key Hyckenberg, Orjan Grelsson, Lars Mattsson, Kjell Karlsson
-
Patent number: 11493489Abstract: The present invention relates to a liquid chromatography system (90) configured to operate with at least one column and configured for purification of a sample comprising a target product using a predefined process. The liquid chromatography system comprises a controller (91) configured to: control the operation of the chromatography system to run the predefined process; retrieve column data accessible from a data storage, the column data being specific to each column; and adapt at least one process parameter of the predefined process for each column based on column data. Whereby the predefined process is adapted to each column to obtain the target product and maintain the performance of the liquid chromatography system.Type: GrantFiled: February 20, 2019Date of Patent: November 8, 2022Assignee: Cytiva Sweden ABInventors: Jens Widehammar, Key Hyckenberg, Orjan Grelsson, Lars Mattsson, Kjell Karlsson
-
Publication number: 20220241406Abstract: The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also 5 shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and/or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.Type: ApplicationFiled: July 2, 2020Publication date: August 4, 2022Inventors: Jonas LIDHOLM, Lars MATTSSON, Angelica EHRENBERG, Håkan LARSSON, Jonas ÖSTLING
-
Publication number: 20220163493Abstract: Disclosed is a chromatography system arranged to perform automated chromatography column efficiency testing for a specific column to determine efficiency parameters such as h and As and optionally to further provide guidance to the user with respect to column efficiency, the system having a controller arranged to automatically access data to enable the calculation of a column compression plate height, said data being derived from at least stored parameters of the specific column and the resin to be used in that column, thereby to calculate the efficiency of the column.Type: ApplicationFiled: April 16, 2020Publication date: May 26, 2022Inventors: Jens Widehammar, Key Hyckenberg, Orjan Grelsson, Lars Mattsson, Kjell Karlsson
-
Publication number: 20220128523Abstract: The present invention relates to a computer-implemented method for controlling preparation of a liquid mixture comprising an acid and its conjugate base or a base and its conjugate acid. The method comprises obtaining (S11) a composition for the liquid mixture to be prepared and determining (S12) a plurality of settings for controlling a preparation of the liquid mixture in one or more automated processes. The plurality of settings are provided (S13) to one or more control systems of the one or more automated processes. The present invention also relates to a buffer tool configured to perform the computer-implemented method, a buffer management system comprising the buffer tool, and a computer readable storage medium (25), having stored thereon a computer program which, when executed in a buffer tool, causes execution of the computer-implemented method.Type: ApplicationFiled: February 24, 2020Publication date: April 28, 2022Inventors: Lars Mattsson, Ioana Erlandsson, Therese Westman, Enrique Carredano, Jenny Dunker
-
Publication number: 20210269888Abstract: The present invention relates to a method for optimizing a bioprocess purification system comprising a bioreactor configured to provide a harvest comprising a target composition, and a purification process arranged downstream the bioreactor and being configured for purification of the harvest to produce a target product having a desired characteristics. The method comprising: a) detecting (32) at least one quality attribute indicative of characteristics of the target product in a downstream process, b) identifying (33) correlations between the at least one quality attribute measured in the downstream process and parameters to control a cell culture process in the bioreactor, and c) controlling (34) the cell culture process to meet the desired characteristics based on the identified correlations, whereby the target characteristics is within a pre-determined range.Type: ApplicationFiled: July 1, 2019Publication date: September 2, 2021Inventors: Key Hyckenberg, Helena Skoglar, Gunnar Malmquist, Mikael Carlsten, Roger Lundqvist, Dan Andersson, Linda Mathiasson, Lars Mattsson, Sara Sendabo, Mikael Berg
-
Publication number: 20210239662Abstract: The present invention relates to a liquid chromatography system (90) configured to operate with at least one column and configured for purification of a sample comprising a target product using a predefined process. The liquid chromatography system comprises a controller (91) configured to: control the operation of the chromatography system to run the predefined process; retrieve column data accessible from a data storage, the column data being specific to each column; and adapt at least one process parameter of the predefined process for each column based on column data. Whereby the predefined process is adapted to each column to obtain the target product and maintain the performance of the liquid chromatography system.Type: ApplicationFiled: February 20, 2019Publication date: August 5, 2021Inventors: Jens Widehammar, Key Hyckenberg, Orjan Grelsson, Lars Mattsson, Kjell Karlsson
-
Patent number: 10753946Abstract: The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70% with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4. The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.Type: GrantFiled: July 20, 2015Date of Patent: August 25, 2020Assignee: PHADIA ABInventors: Lars Mattsson, Ulrica Olsson, Thomas Lundgren, Jonas Lidholm, Håkan Larsson
-
Patent number: 9757447Abstract: Methods for producing an allergen composition, methods for in vitro diagnosis of type I allergy, and diagnostic kits for performing diagnosis employ Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein. Methods for treatment of a Type I allergy to a mammal and pharmaceutical compositions employ a Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein, wherein the Bos d 23k allergen, the mature protein, the variant or the fragment is modified to abrogate or attenuate its IgE binding response.Type: GrantFiled: December 30, 2015Date of Patent: September 12, 2017Assignee: PHADIA ABInventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Patent number: 9724407Abstract: A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having Type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of IgE antibodies specifically binding to the horse allergen, wherein the presence of such IgE antibodies specifically binding to the horse allergen is indicative of Type 1 allergy. A method for treatment of Type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its IgE binding response. The horse allergen may be produced via a vector and a host cell comprising the vector.Type: GrantFiled: September 29, 2015Date of Patent: August 8, 2017Assignee: PHADIA ABInventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Publication number: 20170219602Abstract: The invention relates to a novel horse allergen consisting of a heterodimeric protein having a first peptide chain and a second peptide chain together having an overall sequence identity of at least 70% with the combined sequences of SEQ ID NO:3 and SEQ ID NO: 4, as well as a single chain protein having an overall sequence identity of at least 70%, such as 75%, 80%, 85%, 90%, 95%, or 98%, with the combined amino acid sequences according to SEQ ID NO: 3 and SEQ ID NO: 4. The invention further relates to the use of the protein in methods of diagnosis and therapy of Type I allergy, and kits and compositions for use in such methods.Type: ApplicationFiled: July 20, 2015Publication date: August 3, 2017Applicant: PHADIA ABInventors: Lars MATTSSON, Ulrica OLSSON, Thomas LUNDGREN, Jonas LIDHOLM, Håkan LARSSON
-
Patent number: 9518987Abstract: Methods for treatment of a Type I allergy in a mammal comprise administering to an individual in need of such treatment a polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively, or a hypoallergenic form thereof that is modified to abrogate or attenuate its IgE binding response. Diagnostic kits comprise the polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, immobilized on a solid support.Type: GrantFiled: November 3, 2015Date of Patent: December 13, 2016Assignee: PHADIA ABInventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
-
Publication number: 20160114031Abstract: Methods for producing an allergen composition, methods for in vitro diagnosis of type I allergy, and diagnostic kits for performing diagnosis employ Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein. Methods for treatment of a Type I allergy to a mammal and pharmaceutical compositions employ a Bos d 23k allergen of SEQ ID NO: 4, or the mature protein thereof, or a variant or fragment of the Bos d 23k allergen or the mature protein sharing epitopes for antibodies with the Bos d 23k allergen or the mature protein, wherein the Bos d 23k allergen, the mature protein, the variant or the fragment is modified to abrogate or attenuate its IgE binding response.Type: ApplicationFiled: December 30, 2015Publication date: April 28, 2016Inventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Publication number: 20160082101Abstract: A method for performing in vitro diagnosis of type 1 allergy, comprises contacting an immunoglobulin-containing body fluid sample from a patient suspected of having Type 1 allergy with an immobilized horse allergen immobilized on a solid support, and detecting the presence, in the sample, of IgE antibodies specifically binding to the horse allergen, wherein the presence of such IgE antibodies specifically binding to the horse allergen is indicative of Type 1 allergy. A method for treatment of Type 1 allergy comprises administering to an individual susceptible to such treatment, the horse allergen, or a form of the horse allergen that is modified to abrogate or attenuate its IgE binding response. The horse allergen may be produced via a vector and a host cell comprising the vector.Type: ApplicationFiled: September 29, 2015Publication date: March 24, 2016Inventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Patent number: 9274114Abstract: Methods for in vitro diagnosis of type I allergy comprises the steps of contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type I allergy with a variant or fragment of the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, which variant or fragment shares epitopes for antibodies with the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1; and detecting the presence, in the sample, of IgE antibodies specifically binding to the variant or fragment. The presence of such IgE antibodies specifically binding to the variant or fragment is indicative of a type I allergy in the patient.Type: GrantFiled: May 13, 2014Date of Patent: March 1, 2016Assignee: Phadia ABInventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
-
Publication number: 20160051666Abstract: Methods for treatment of a Type I allergy in a mammal comprise administering to an individual in need of such treatment a polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, or a fragment of the polypeptide or the mature protein, which fragment shares epitopes for antibodies with the polypeptide or the mature protein, respectively, or a hypoallergenic form thereof that is modified to abrogate or attenuate its IgE binding response. Diagnostic kits comprise the polypeptide of SEQ ID NO: 1 or the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, immobilized on a solid support.Type: ApplicationFiled: November 3, 2015Publication date: February 25, 2016Inventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
-
Patent number: 9243045Abstract: The present invention refers to the field of allergy. More specifically, the invention relates to the identification of new allergens from mammals and to diagnosis and treatment of allergy towards mammals. In particular the invention relates to a recombinantly produced canine allergen, Can f 4, or bovine allergen, Bos d 23k, or variants or fragments thereof sharing epitopes with the wildtype allergen, and the use thereof for the manufacture of a diagnostic composition as well as methods for in vitro diagnosis and treatment of allergy.Type: GrantFiled: June 4, 2010Date of Patent: January 26, 2016Assignee: PHADIA ABInventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Patent number: 9182400Abstract: Prostatic kallikrein for the manufacture of a diagnostic or pharmaceutical composition for diagnosis/treatment of type 1 allergy, especially allergy to dogs.Type: GrantFiled: December 21, 2007Date of Patent: November 10, 2015Assignee: PHADIA ABInventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg
-
Patent number: 9164101Abstract: An isolated horse allergen is disclosed which is a secretoglobin having a molecular weight of 15 kDa under non-reducing conditions and comprising a first peptide chain having a molecular weight of about 5 kDa and a second peptide chain having a molecular weight of about 10 kDa linked together, and variants and fragments thereof sharing epitopes for antibodies therewith. The use of the allergen in diagnosis and therapy is also disclosed as well as a diagnostic kit and a pharmaceutical composition containing the allergen.Type: GrantFiled: April 26, 2011Date of Patent: October 20, 2015Assignee: Phadia ABInventors: Lars Mattsson, Jonas Lidholm, Thomas Lundgren
-
Publication number: 20140249048Abstract: Methods for in vitro diagnosis of type I allergy comprises the steps of contacting an immunoglobulin-containing body fluid sample from a patient suspected of having type I allergy with a variant or fragment of the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1, which variant or fragment shares epitopes for antibodies with the mature protein, amino acids 25-260, of the polypeptide of SEQ ID NO: 1; and detecting the presence, in the sample, of IgE antibodies specifically binding to the variant or fragment. The presence of such IgE antibodies specifically binding to the variant or fragment is indicative of a type I allergy in the patient.Type: ApplicationFiled: May 13, 2014Publication date: September 4, 2014Applicant: Phadia ABInventors: Lars Mattsson, Jonas Lidholm, Henrik Everberg